Industry Should Outsource R&D To Manage Drug Development Costs, HGS CEO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Nearly all aspects of the drug development process can be done in other countries at substantial savings, Human Genome Sciences' Haseltine says. Outsourcing could reduce costs by up to two-thirds and allow greater flexibility, he maintains.
You may also be interested in...
GSK Predicts Outsourcing R&D To “Low-Cost” Countries Could Save $200 Mil.
Each outsourced clinical trial patient could save GSK up to $15,000, CEO Garnier estimates. The company is exploring a number of ways to control R&D costs, the exec says, citing electronic data capture as another potential option.
GSK Predicts Outsourcing R&D To “Low-Cost” Countries Could Save $200 Mil.
Each outsourced clinical trial patient could save GSK up to $15,000, CEO Garnier estimates. The company is exploring a number of ways to control R&D costs, the exec says, citing electronic data capture as another potential option.
HGS To Focus On "Core Pipeline" As Part Of Cost Reduction Plan; CEO Steps Down
Human Genome Sciences plans to reduce its headcount by 20% and limit the number of drugs in early development. In 2004 and 2005, the company will focus on five products in immunology/infectious disease and oncology.